MAPT and Alzheimer disease: The relevance of this result is particularly important because current biomarkers of AD, such as cerebrospinal fluid tau/Aβ fragments and positron emission tomography amyloid imaging, are known to change non-linearly throughout the progression of AD (Jack et al., 2013).